164 related articles for article (PubMed ID: 17131241)
1. Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes.
Westerfeld N; Pluschke G; Zurbriggen R
Wien Klin Wochenschr; 2006; 118(19-20 Suppl 3):50-7. PubMed ID: 17131241
[TBL] [Abstract][Full Text] [Related]
2. Peptides delivered by immunostimulating reconstituted influenza virosomes.
Westerfeld N; Zurbriggen R
J Pept Sci; 2005 Nov; 11(11):707-12. PubMed ID: 16059967
[TBL] [Abstract][Full Text] [Related]
3. Influenza virosomes as an efficient system for adjuvanted vaccine delivery.
Glück R; Moser C; Metcalfe IC
Expert Opin Biol Ther; 2004 Jul; 4(7):1139-45. PubMed ID: 15268680
[TBL] [Abstract][Full Text] [Related]
4. Influenza virosomes: a flu jab for malaria?
Cavanagh DR; Remarque EJ; Sauerwein RW; Hermsen CC; Luty AJ
Trends Parasitol; 2008 Sep; 24(9):382-5. PubMed ID: 18684667
[TBL] [Abstract][Full Text] [Related]
5. The virosome concept for influenza vaccines.
Huckriede A; Bungener L; Stegmann T; Daemen T; Medema J; Palache AM; Wilschut J
Vaccine; 2005 Jul; 23 Suppl 1():S26-38. PubMed ID: 16026906
[TBL] [Abstract][Full Text] [Related]
6. Influenza virosomes as a vaccine adjuvant and carrier system.
Moser C; Amacker M; Zurbriggen R
Expert Rev Vaccines; 2011 Apr; 10(4):437-46. PubMed ID: 21506642
[TBL] [Abstract][Full Text] [Related]
7. Influenza vaccines: the virosome concept.
Wilschut J
Immunol Lett; 2009 Feb; 122(2):118-21. PubMed ID: 19100779
[TBL] [Abstract][Full Text] [Related]
8. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells.
Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R
Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436
[TBL] [Abstract][Full Text] [Related]
9. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees.
BenMohamed L; Gras-Masse H; Tartar A; Daubersies P; Brahimi K; Bossus M; Thomas A; Druilhe P
Eur J Immunol; 1997 May; 27(5):1242-53. PubMed ID: 9174617
[TBL] [Abstract][Full Text] [Related]
10. Influenza virosomes in vaccine development.
Huckriede A; Bungener L; Daemen T; Wilschut J
Methods Enzymol; 2003; 373():74-91. PubMed ID: 14714397
[TBL] [Abstract][Full Text] [Related]
11. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro.
Schumacher R; Amacker M; Neuhaus D; Rosenthal R; Groeper C; Heberer M; Spagnoli GC; Zurbriggen R; Adamina M
Vaccine; 2005 Dec; 23(48-49):5572-82. PubMed ID: 16165256
[TBL] [Abstract][Full Text] [Related]
12. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems.
Glück R; Metcalfe IC
Vaccine; 2003 Jan; 21(7-8):611-5. PubMed ID: 12531327
[TBL] [Abstract][Full Text] [Related]
13. Molecular vaccines for malaria.
Bruder JT; Angov E; Limbach KJ; Richie TL
Hum Vaccin; 2010 Jan; 6(1):54-77. PubMed ID: 20061792
[TBL] [Abstract][Full Text] [Related]
14. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
Bungener L; Huckriede A; de Mare A; de Vries-Idema J; Wilschut J; Daemen T
Vaccine; 2005 Jan; 23(10):1232-41. PubMed ID: 15652665
[TBL] [Abstract][Full Text] [Related]
15. Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites.
Tsuji M; Zavala F
Mol Immunol; 2001 Dec; 38(6):433-42. PubMed ID: 11741693
[TBL] [Abstract][Full Text] [Related]
16. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial.
Peduzzi E; Westerfeld N; Zurbriggen R; Pluschke G; Daubenberger CA
Clin Immunol; 2008 May; 127(2):188-97. PubMed ID: 18337175
[TBL] [Abstract][Full Text] [Related]
17. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.
Abdoli A; Soleimanjahi H; Tavassoti Kheiri M; Jamali A; Mazaheri V; Abdollahpour Alitappeh M
Pathog Dis; 2014 Dec; 72(3):197-207. PubMed ID: 25066138
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
[TBL] [Abstract][Full Text] [Related]
19. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
[TBL] [Abstract][Full Text] [Related]
20. Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge.
Kheiri MT; Jamali A; Shenagari M; Hashemi H; Sabahi F; Atyabi F; Saghiri R
Antiviral Res; 2012 Sep; 95(3):229-36. PubMed ID: 22809863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
